The relationship between neurotrophins and bipolar disorder

Expert Review of Neurotherapeutics

Volumn 14, Issue 1, 2014, Pages 51-65

  Wu, Renrong ^a   Fan, Jinbo ^b,c   Zhao, Jingping ^a   Calabrese, Joseph R ^b   Gao, Keming ^b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bipolar disorder; Brain derived neurotrophic factor; Cognitive performance; Genetic association study; Major depressive disorder; Neuroimaging; Neurotrophins; Pharmacogenetic; Schizophrenia; Serum chemistry

Indexed keywords

ADIPONECTIN; ANTICONVULSIVE AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; C REACTIVE PROTEIN; CARBAMAZEPINE; INTERLEUKIN 6; LAMOTRIGINE; LITHIUM; MESSENGER RNA; NEUROTROPHIC TYROSINE KINASE RECEPTOR 3; NEUROTROPHIN; PROTEIN TYROSINE KINASE A; QUETIAPINE; RISPERIDONE; STABILIZING AGENT; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VALPROIC ACID;

ALLELE; AMINO ACID SUBSTITUTION; BDNF GENE; BIPOLAR DISORDER; BIPOLAR I DISORDER; BIPOLAR II DISORDER; BRAIN REGION; CACNA1C GENE; CLINICAL TRIAL (TOPIC); COGNITION; COMORBIDITY; DEPRESSION; ELECTROCONVULSIVE THERAPY; EXECUTIVE FUNCTION; GENE; GENE EXPRESSION; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE; GRAY MATTER; HAPLOTYPE; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; MANIA; MONOTHERAPY; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOGENESIS; PHARMACOGENOMICS; REVIEW; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESISTANT DEPRESSION; TREATMENT RESPONSE;

ANIMALS; BIPOLAR DISORDER; BRAIN-DERIVED NEUROTROPHIC FACTOR; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NERVE GROWTH FACTORS;

EID: 84893030563     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.2014.863709     Document Type: Review

References (131)

1. Merikangas KR, Akiskal HS, Angst J et al. Lifetime and 12-month prevalence ofbipolar spectrum disorder in the national comorbidity survey replication. Arch. Gen. Psychiatry 64(5), 543-552 (2007
2. Merikangas KR, Jin R, He JP et al. Prevalence and Correlates of Bipolar Spectrum Disorder in the World Mental Health Survey Initiative. Arch. Gen. Psychiatry 68(3), 241-251 (2011
3. Wyatt RJ, Henter I. An economic evaluation of manic-depressive illness-1991. Soc. Psychiatry Psychiatr. Epidemiol. 30(5), 213-219 (1995
4. Gao K, Kemp DE, Wu R et al. Mood Stabilizers. In: Psychiatry (4th Edition). Tasman A, Liberman J, Kay J, First M, Riba M (Eds). John Wiley and Sons, Ltd., West Sussex, UK (In Press
5. Gao K, Wu R, Grunze H et al. Phamarcological treatment of acute bipolar depression. In: Bipolar Disorder: Mellinium Upate.Yildiz A, Nemeroff C, Ruiz P (Eds), Oxford University Press, New York, USA (In Press
6. Gao K, Kemp DE, Calabrese Jr. Pharmacological treatment of the maintenance phase of bipolar depression: Faocus on relapse prevention studies and the impact of design on generalizability.In: Milestones in Drug Therapy, Bipolar Depression: Molecular Neurobiology, Clinical Diagnosis and Pharmacotherapy. Zarate CA, Manji HK (Ed.), Spinger, Birkhauser Vertag, Switzerland, 159-178 (2009
7. Longo FM, Xie Y, Massa SM. Neurophin small molecule mimetics: Candidate therapeutic agents for neurological disorders. Curr. Med. Chem. - Central Nervous System Agents 5, 26-41 (2005
8. Duman RS. Novel therapeutic approaches beyond the serotonin receptor. Biol. Psychiatry 44(5), 324-35 (1998
9. Craddock N, Jones I. Genetics of bipolar disorder. J. Med. Genet. 36(8), 585-594 (1999
10. Craddock N, Lendon C, Cichon S et al. Chromosome Workshop: Chromosomes 11, 14, and 15. Am. J. Med. Genet. 88(3), 244-254 (1999
11. Cargill M, Altshuler D, Ireland J et al. Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat. Genet. 22(3), 231-238 (1999
12. Sklar P, Gabriel SB, McInnis MG et al. Family-based association study of 76 candidate genes in bipolar disorder: BDNF is a potential risk locus. Brain-derived neutrophic factor. Mol. Psychiatry 7(6), 579-593 (2002
13. Neves-Pereira M, Mundo E, Muglia P et al. The brain-derived neurotrophic factor gene confers susceptibility to bipolar disorder: Evidence from a family-based association study. Am. J. Hum. Genet. 71(3), 651-655 (2002
14. Geller B, Badner JA, Tillman R et al. Linkage disequilibrium of the brain-derived neurotrophic factor Val66Met polymorphism in children with a prepubertal and early adolescent bipolar disorder phenotype. Am. J. Psychiatry 161(9), 1698-1700 (2004
15. Kremeyer B, Herzberg I, Garcia J et al. Transmission distortion of BDNF variants to bipolar disorder type I patients from a South American population isolate. Am. J. Med. Genet. B Neuropsychiatr. Genet. 141B(5), 435-439 (2006
16. Lohoff FW, Sander T, Ferraro TN et al. Confirmation of association between the Val66Met polymorphism in the brain-derived neurotrophic factor (BDNF) gene and bipolar I disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet. 139B(1), 51-53 (2005
17. Muller DJ, De Luca V, Sicard T et al. Brain-derived neurotrophic factor (BDNF) gene and rapid-cycling bipolar disorder - Family-based association study. Br. J. Psychiatry 189, 317-323 (2006
18. Liu LX, Foroud T, Xuei XL et al. Evidence of association between brain-derived neurotrophic factor gene and bipolar disorder. Psychiatr. Genet. 18(6), 267-274 (2008
19. Wang Z, Li Z, Chen J et al. Association of BDNF gene polymorphism with bipolar disorders in Han Chinese Population. Genes Brain Behav. 11(5), 524-528 (2012
20. Ivanova MA, Christova TN, Asan TS et al. Evidence of an association between bipolar disorder and rs16917237 in the BDNF gene in a Bulgarian sample. Psychiatr. Genet. 23(3), 141-142 (2013
21. Xu J, Liu Y, Wang P et al. Positive association between the brain-derived neurotrophic factor (BDNF) gene and bipolar disorder in the Han Chinese Population. Am. J. Med. Genet. B Neuropsychiatr. Genet. 153B(1), 275-279 (2010
22. Nakata K, Ujike H, Sakai A et al. Association study of the brain-derived neurotrophic factor (BDNF) gene with bipolar disorder. Neurosci. Lett. 337(1), 17-20 (2003
23. Hong CJ, Huo SJ, Yen FC et al. Association study of a brain-derived neurotrophic-factor genetic polymorphism and mood disorders, age of onset and suicidal behavior. Neuropsychobiology 48(4), 186-189 (2003
24. Neves-Pereira M, Cheung J, Pasdar A et al. BDNF gene is a risk factor for schizophrenia in a Scottish population. Mol. Psychiatry 10(2), 208-212 (2005
25. Oswald P, Del-Favero J, Massat I et al. Non-replication of the brain-derived neurotrophic factor (BDNF) association in bipolar affective disorder: A Belgian patient-control study. Am. J. Med. Genet. B Neuropsychiatr. Genet. 129B(1), 34-35 (2004
26. Skibinska M, Hauser J, Czerski PM et al. Association analysis of brain-derived neurotrophic factor (BDNF) gene Val66Met polymorphism in schizophrenia and bipolar affective disorder. World J. Biol. Psychiatry 5(4), 215-220 (2004
27. Craddock N, Forty L. Genetics of affective (mood) disorders. Eur. J. Hum. Genet. 14(6), 660-668 (2006
28. Green EK, Raybould R, MacGregor S et al. Genetic variation of brain-derived neurotrophic factor (BDNF) in bipolar disorder - Case-control study of over 3000 individuals from the UK. Br. J. Psychiatry 188, 21-25 (2006
29. Ye CY, Xu YQ, Hu H et al. [An association study of brain-derived neurotrophic factor gene polymorphism in bipolar disorders]. Zhonghua yi xue za zhi 89(27), 1897-1901 (2009
30. Fan J, Sklar P. Genetics of bipolar disorder: Faocus on BDNF Val66Met polymorphism. Novartis Foundation symposium 289, 60-72 (2008
31. Min HJ, Cho HS, Kim SJ et al. Association of the brain-derived neurotrophic factor gene and clinical features of bipolar disorder in Korea. Clin. Psychopharmacol. Neurosci. 10(3), 163-167 (2012
32. Rybakowski JK, Borkowska A, Czerski PM et al. Polymorphism of the brain-derived neurotrophic factor gene and performance on a cognitive prefrontal test in bipolar patients. Bipolar Disord. 5(6), 468-472 (2003
33. Tang J, Xiao L, Shu C et al. Association of the brain-derived neurotrophic factor gene and bipolar disorder with early age of onset in mainland China. Neurosci.Lett. 433(2), 98-102 (2008
34. Strauss J, Barr CL, George CJ et al. Association study of brain-derived neurotrophic factor in adults with a history of childhood onset mood disorder. Am. J. Med. Gene.t B Neuropsychiatr. Genet. 131B(1), 16-19 (2004
35. Adams JH, Wigg KG, King N et al. Association study of neurotrophic tyrosine kinase receptor type 2 (NTRK2) and childhood-onset mood disorders. Am. J. Med. Genet. B Neuropsychiat.r Genet. 132B(1), 90-95 (2005
36. Rybakowski JK, Borkowska A, Skibinska M et al. Illness-specific association of val66met BDNF polymorphism with performance on Wisconsin Card Sorting Test in bipolar mood disorder. Mol. Psychiatry 11(2), 122-124 (2006
37. Moreira L, Neves FS, Romano-Silva MA et al. BDNF and episodic memory in patients with bipolar disorder. Rev. Bras. Psiquiatr. 33(1), 96-97 (2011
38. Gruber O, Hasan A, Scherk H et al. Association of the brain-derived neurotrophic factor val66met polymorphism with magnetic resonance spectroscopic markers in the human hippocampus: In vivo evidence for effects on the glutamate system. Eur. Arch. Psychiatry Clin. Neurosci. 262(1), 23-31 (2012
39. Tramontina JF, Yates D, Magalhaes PVD et al. Brain-derived neurotrophic factor gene val66met polymorphism and executive functioning in patients with bipolar disorder. Rev. Bras. Psiquiatr. 31(2), 136-140 (2009
40. Zeni CP, Tramontina S, Zeni TA et al. The Val66Met polymorphism at the BDNF gene does not influence Wisconsin Card Sorting Test results in children and adolescents with bipolar disorder. Rev. Bras. Psiquiatr. 35(1), 44-50 (2013
41. Joseph MF, Frazier TW, Youngstrom EA et al. A quantitative and qualitative review of neurocognitive performance in pediatric bipolar disorder. J. Child Adolesc. Psychopharmacol. 18(6), 595-605 (2008
42. Vohringer PA, Barroilhet SA, Amerio A et al. Cognitive impairment in bipolar disorder and schizophrenia: A systematic review. Front. Psychiatry 4, 87 (2013
43. Gao K, Wang Z, Chen J et al. Should an assessment of Axis I comorbidity be included in the initial diagnostic assessment of mood disorders? Role of QIDS-16-SR total score in predicting number of Axis I comorbidity. J. Affect. Disord. 148(2-3), 256-264 (2013
44. Neves FS, Malloy-Diniz L, Romano-Silva MA et al. The role of BDNF genetic polymorphisms in bipolar disorder with psychiatric comorbidities. J. Affect. Disord. 131(1-3), 307-311 (2011
45. Koppel I, Aid-Pavlidis T, Jaanson K et al. Tissue-specific and neural activity-regulated expression of human BDNF gene in BAC transgenic mice. BMC Neurosci. 10, 68 (2009
46. Pandey GN, Dwivedi Y. Brain-derived neurotrophic factor gene and protein expression in pediatric and adult depressed subjects. Prog. Neuropsychopharmacol Biol. Psychiatry 34(6), 1161-1161 (2010
47. Pandey GN, Rizavi HS, Dwivedi Y et al. Brain-derived neurotrophic factor gene expression in pediatric bipolar disorder: Effects of treatment and clinical response. J. Am. Acad. Child Adolesc. Psychiatry 47(9), 1077-1085 (2008
48. D'Addario C, Dell'Osso B, Palazzo MC et al. Selective DNA Methylation of BDNF promoter in bipolar disorder: Differences among patients with BDI and BDII. Neuropsychopharmacology 37(7), 1647-1655 (2012
49. Dunham JS, Deakin JFW, Miyajima F et al. Expression of hippocampal brain-derived neurotrophic factor and its receptors in Stanley consortium brains. J. Psychiatr. Res. 43(14), 1175-1184 (2009
50. Pillai A. Decreased expression of sprouty2 in the dorsolateral prefrontal cortex in schizophrenia and bipolar disorder: A positive correlation with BDNF expression. Biol. Psychiatry 63(7), 107s (2008
51. Thompson Ray M, Weickert CS, Wyatt E et al. Decreased BDNF, trkB-TK+ and GAD67 mRNA expression in the hippocampus of individuals with schizophrenia and mood disorders. J. Psychiatry Neurosci. 36(3), 195-203 (2011
52. Soontornniyomkij B, Everall IP, Chana G et al. Tyrosine kinase B protein expression is reduced in the cerebellum of patients with bipolar disorder. J. Affect. Disord. 133(3), 646-654 (2011
53. De Luca V, Strauss J, Semeralul M et al. Analysis of BDNF Val66Met allele-specific mRNA levels in bipolar disorder. Neurosci. Lett. 441(2), 229-232 (2008
54. Munkholm K, Vinberg M, Berk M et al. State-related alterations of gene expression in bipolar disorder: A systematic review. Bipolar Disord. 14(7), 684-696 (2012
55. Chepenik LG, Fredericks C, Papademetris X et al. Effects of the brain-derived neurotrophic growth factor Val66Met variation on hippocampus morphology in bipolar disorder. Neuropsychopharmacology 34(4), 944-951 (2009
56. Matsuo K, Walss-Bass C, Nery FG et al. Neuronal correlates of brain-derived neurotrophic factor Val66Met polymorphism and morphometric abnormalities in bipolar disorder. Neuropsychopharmacology 34(8), 1904-1913 (2009
57. Frodl T, Schuele C, Schmitt G et al. Association of the brain-derived neurotrophic factor Val66Met polymorphism with reduced hippocampal volumes in major depression. Arch. Gen. Psychiatry 64(4), 410-416 (2007
58. Montag C, Weber B, Fliessbach K et al. The BDNF Val66Met polymorphism impacts parahippocampal and amygdala volume in healthy humans: Incremental support for a genetic risk factor for depression. Psychol. Med. 39(11), 1831-1839 (2009
59. Teh CA, Lee TS, Kuchibhatla M et al. Bipolar disorder, brain-derived neurotrophic factor (BDNF) Val66Met polymorphism and brain morphology. PloS ONE 7(7), e38469 (2012
60. Selvaraj S, Arnone D, Job D et al. Grey matter differences in bipolar disorder: A meta-analysis of voxel-based morphometry studies. Bipolar Disord. 14(2), 135-145 (2012
61. Hafeman DM, Chang KD, Garrett AS et al. Effects of medication on neuroimaging findings in bipolar disorder: An updated review. Bipolar Disord. 14(4), 375-410 (2012
62. Mirakhur A, Moorhead TW, Stanfield AC et al. Changes in gyrification over 4 years in bipolar disorder and their association with the brain-derived neurotrophic factor valine (66) methionine variant. Biol. Psychiatry 66(3), 293-297 (2009
63. McIntosh AM, Moorhead TW, McKirdy J et al. Temporal grey matter reductions in bipolar disorder are associated with the BDNF Val66Met polymorphism. Mol. Psychiatry 12(10), 902-903 (2007
64. Frey BN, Walss-Bass C, Stanley JA et al. Brain-derived neurotrophic factor val66met polymorphism affects prefrontal energy metabolism in bipolar disorder. Neuroreport 18(15), 1567-1570 (2007
65. Gallinat J, Schubert F, Bruhl R et al. Met carriers of BDNF Val66Met genotype show increased N-acetylaspartate concentration in the anterior cingulate cortex. Neuroimage 49(1), 767-771 (2010
66. Tsai SJ. Is mania caused by overactivity of central brain-derived neurotrophic factor? Med. Hypotheses 62(1), 19-22 (2004
67. Machado-Vieira R, Dietrich MO, Leke R et al. Decreased plasma brain derived neurotrophic factor levels in unmedicated bipolar patients during manic episode. Biol. Psychiatry 61(2), 142-144 (2007
68. de Oliveira GS, Cereser KM, Fernandes BS et al. Decreased brain-derived neurotrophic factor in medicated and drug-free bipolar patients. J. Psychiatr. Res. 43(14), 1171-1174 (2009
69. Cunha AB, Frey BN, Andreazza AC et al. Serum brain-derived neurotrophic factor is decreased in bipolar disorder during depressive and manic episodes. Neurosci. Lett. 398(3), 215-219 (2006
70. Fernandes BS, Gama CS, Kauer-Sant' Anna M et al. Serum brain-derived neurotrophic factor in bipolar and unipolar depression: A potential adjunctive tool for differential diagnosis. J. Psychiatr. Res. 43(15), 1200-1204 (2009
71. Chou YH, Wang SJ, Lirng JF et al. Impaired cognition in bipolar I disorder: The roles of the serotonin transporter and brain-derived neurotrophic factor. J. Affect. Disord. 143(1-3), 131-137 (2012
72. Dias VV, Brissos S, Frey BN et al. Cognitive function and serum levels of brain-derived neurotrophic factor in patients with bipolar disorder. Bipolar Disord. 11(6), 663-671 (2009
73. Huang TL, Hung YY, Lee CT et al. Serum protein levels of brain-derived neurotrophic factor and tropomyosin-related kinase B in bipolar disorder: Effects of mood stabilizers. Neuropsychobiology 65(2), 65-69 (2012
74. Monteleone P, Serritella C, Martiadis V et al. Decreased levels of serum brain-derived neurotrophic factor in both depressed and euthymic patients with unipolar depression and in euthymic patients with bipolar I and II disorders. Bipolar Disord. 10(1), 95-100 (2008
75. Hashimoto K. Brain-derived neurotrophic factor as a biomarker for mood disorders: An historical overview and future directions. Psychiatry Clin. Neurosci. 64(4), 341-357 (2010
76. Barbosa IG, Huguet RB, Mendonca VA et al. Increased plasma levels of brain-derived neurotrophic factor in patients with long-term bipolar disorder. Neurosci. Lett. 475(2), 95-98 (2010
77. Barbosa IG, Rocha NP, Huguet RB et al. Executive dysfunction in euthymic bipolar disorder patients and its association with plasma biomarkers. J. Affect. Disord. 137(1-3), 151-155 (2012
78. Barbosa IG, Rocha NP, de Miranda AS et al. Increased BDNF levels in long-term bipolar disorder patients. Rev. Bras. Psiquiatr. 35(1), 67-69 (2013
79. Lin PY. State-dependent decrease in levels of brain-derived neurotrophic factor in bipolar disorder: A meta-analytic study. Neurosci. Lett. 466(3), 139-143 (2009
80. Fernandes BS, Gama CS, Cereser KM et al. Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: A systematic review and meta-regression analysis. J. Psychiatr. Res. 45(8), 995-1004 (2011
81. Rybakowski JK, Suwalska A. Excellent lithium responders have normal cognitive functions and plasma BDNF levels. Int. J. Neuropsychophamcol. 13(5), 617-622 (2010
82. Suwalska A, Sobieska M, Rybakowski JK. Serum brain-derived neurotrophic factor in euthymic bipolar patients on prophylactic lithium therapy. Neuropsychobiology 62(4), 229-234 (2010
83. Tramontina JF, Andreazza AC, Kauer-Sant' Anna M et al. Brain-derived neurotrophic factor serum levels before and after treatment for acute mania. Neurosci. Lett. 452(2), 111-113 (2009
84. de Sousa RT, van de Bilt MT, Diniz BS et al. Lithium increases plasma brain-derived neurotrophic factor in acute bipolar mania: A preliminary 4-week study. Neurosci. Lett. 494(1), 54-56 (2011
85. Tseng M, Alda M, Xu L et al. BDNF protein levels are decreased in transformed lymphoblasts from lithium-responsive patients with bipolar disorder. J. Psychiatry Neurosci. 33(5), 449-453 (2008
86. Yoshimura R,Nakano Y, Hori H et al. Effect of risperidone on plasma catecholamine metabolites and brain-derived neurotrophic factor in patients with bipolar disorders. Hum. Psychopharmacol. 21(7), 433-438 (2006
87. Grande I, Kapczinski F, Stertz L et al. Peripheral brain-derived neurotrophic factor changes along treatment with extended release quetiapine during acute mood episodes: An open-label trial in drug-free patients with bipolar disorder. J. Psychiatr. Res. 46(11), 1511-1514 (2012
88. Yoshimura R, Ikenouchi-Sugita A, Hori H et al. Adding a low dose atypical antipsychotic drug to an antidepressant induced a rapid increase of plasma brain-derived neurotrophic factor levels in patients with treatment-resistant depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 34(2), 308-312 (2010
89. Fernandes B, Gama CS, Massuda R et al. Serum brain-derived neurotrophic factor (BDNF) is not associated with response to electroconvulsive therapy (ECT): A pilot study in drug resistant depressed patients. Neurosci. Lett. 453(3), 195-198 (2009
90. D'Sa C, Dileone RJ, Anderson GM et al. Serum and plasma brain-derived neurotrophic factor (BDNF) in abstinent alcoholics and social drinkers. Alcohol 46(3), 253-259 (2012
91. Vinberg M, Trajkovska V, Bennike B et al. The BDNF Val66Met polymorphism: Relation to familiar risk of affective disorder, BDNF levels and salivary cortisol. Bipolar Disord. 11, 12-13 (2009
92. Hosang GM, Uher R, Keers R et al. Stressful life events and the brain-derived neurotrophic factor gene in bipolar disorder. J. Affect. Disord. 125(1-3), 345-349 (2010
93. Schule C, Zill P, Baghai TC et al. Brain-derived neurotrophic factor Val66Met polymorphism and dexamethasone/CRH test results in depressed patients. Psychoneuroendocrinology 31(8), 1019-1025 (2006
94. Miller S, Hallmayer J, Wang PW et al. Brain-derived neurotrophic factor val66met genotype and early life stress effects upon bipolar course. J. Psychiatr. Res. 47(2), 252-258 (2013
95. Chen J, Fang Y, Kemp DE et al. Switching to Hypomania and Mania: Differential Neurochemical, Neuropsychological, and Pharmacologic Triggers and Their Mechanisms. Curr. Psychiatry Rep. 12(6), 512-521 (2010
96. Wu R, Gao K, Calabrese JR et al. Treatment Induced Mood Instability: Treatment - Emergent Affective Switches and Cycle Acceleration. In: Bipolar Disorder: Millennium Update. Yildiz A, Nemeroff C, Ruiz P (Eds), Oxford University Press, New York, USA, in press
97. Vincze I, Perroud N, Buresi C et al. Association between brain-derived neurotrophic factor gene and a severe form of bipolar disorder, but no interaction with the serotonin transporter gene. Bipolar Disord.10(5), 580-587 (2008
98. Lee S-Y, Chen S-L, Wang Y-S et al. COMT and BDNF interacted in bipolar II disorder not comorbid with anxiety disorder. Behav. Brain Res. 237(0), 243-248 (2013
99. Huang CC, Chang YH, Lee SY et al. The interaction between BDNF and DRD2 in bipolar II disorder but not in bipolar I disorder. Am. J Med. Genet. B Neuropsychiatr. Genet. 2159B(5), 501-507 (2012
100. Lee SY, Lu RB. Interaction of the DRD3 and BDNF gene variants in subtype bipolar disorder. Bipolar Disord. 14, 96-96 (2012
101. Goldstein BI, Kemp DE, Soczynska JK et al. Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: A systematic review of the literature. J. Clin. Psychiatry 70(8), 1078-1090 (2009
102. Su SC, Sun MT, Wen MJ et al. Brain-derived neurotrophic factor, adiponectin, and proinflammatory markers in various subtypes of depression in young men. Int. J. Psychiatry Med. 42(3), 211-226 (2011
103. Goldstein BI, Collinger KA, Lotrich F et al. Preliminary findings regarding proinflammatory markers and brain-derived neurotrophic factor among adolescents with bipolar spectrum disorders. J. Child Adolesc. Psychopharmacol. 21(5), 479-484 (2011
104. Kauer-Sant'Anna M, Kapczinski F, Andreazza AC et al. Brain-derived neurotrophic factor and inflammatory markers in patients with early- vs. late-stage bipolar disorder. Int. J. Neuropsychopharmacol. 12(4), 447-458 (2009
105. Rybakowski JK, Suwalska A, Skibinska M et al. Prophylactic lithium response and polymorphism of the brain-derived neurotrophic factor gene. Pharmacopsychiatry 38(4), 166-170 (2005
106. Dmitrzak-Weglarz M, Rybakowski JK, Suwalska A et al. Association studies of the BDNF and the NTRK2 gene polymorphisms with prophylactic lithium response in bipolar patients. Pharmacogenomics 9(11), 1595-1603 (2008
107. Masui T, Hashimoto R, Kusumi I et al. Lithium response and Val66Met polymorphism of the brain-derived neurotrophic factor gene in Japanese patients with bipolar disorder. Psychiatr. Genet. 16(2), 49-50 (2006
108. Michelon L, Meira-Lima I, Cordeiro Q et al. Association study of the INPP1, 5HTT, BDNF, AP-2beta and GSK-3beta GENE variants and restrospectively scored response to lithium prophylaxis in bipolar disorder. Neurosci. Lett. 403(3), 288-293 (2006
109. Rybakowski JK, Suwalska A, Skibinska M et al. Response to lithium prophylaxis: Interaction between serotonin transporter and BDNF genes. Am. J. Med. Genet. B Neuropsychiatr. Genet. 144B(6), 820-823 (2007). predictor(s) of treatment response
110. Severino G, Squassina A, Costa M et al. Pharmacogenomics of bipolar disorder. Pharmacogenomics 14(6), 655-674 (2013
111. Chiu C-T, Chuang D-M. Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders. Pharmacol. Ther. 128(2), 281-304 (2010
112. Machado-Vieira R, Manji HK, Zarate CA. The role of lithium in the treatment of bipolar disorder: Convergent evidence for neurotrophic effects as a unifying hypothesis. Bipolar Disord. 11, 92-109 (2009
113. Gupta A, Schulze TG, Nagarajan V et al. Interaction networks of lithium and valproate molecular targets reveal a striking enrichment of apoptosis functional clusters and neurotrophin signaling. Pharmacogenomics J. 12(4), 328-341 (2012
114. Malhi GS, Tanious M, Das P et al. Potential mechanisms of action of lithium in bipolar disorder current understanding. CNS Drugs 27(2), 135-153 (2013
115. McQuillin A, Rizig M, Gurling HM. A microarray gene expression study of the molecular pharmacology of lithium carbonate on mouse brain mRNA to understand the neurobiology of mood stabilization and treatment of bipolar affective disorder. Pharmacogenet. Genomics 17(8), 605-617 (2007
116. Li N, He X, Qi X et al. The mood stabilizer lamotrigine produces antidepressant behavioral effects in rats: Role of brain-derived neurotrophic factor. J. Psychopharmacol. 24(12), 1772-1778 (2010
117. Li N, He X, Zhang Y et al. Brain-derived neurotrophic factor signalling mediates antidepressant effects of lamotrigine. Int. J. Neuropsychopharmacol. 14(8), 1091-1098 (2011
118. Hammonds MD, Shim SS. Effects of 4-week treatment with lithium and olanzapine on levels of brain-derived neurotrophic factor, B-cell CLL/lymphoma 2 and phosphorylated cyclic adenosine monophosphate response element-binding protein in the sub-regions of the hippocampus. Basic Clin. Pharmacol. Toxicol. 105(2), 113-119 (2009
119. Zai G, Mundo E, Strauss J et al. Brain-derived neurotrophic factor (BDNF) gene not associated with antidepressant-induced mania. Bipolar Disord. 9(5), 521-525 (2007
120. de Aguiar Ferreira A, Neves FS, Pimenta GJ et al. The role of genetic variation of BDNF gene in antidepressant-induced mania in bipolar disorder. Psychiatry Res. 180(1), 54-56 (2010
121. Feng Y, Vetro A, Kiss E et al. Association of the neurotrophic tyrosine kinase receptor 3 (NTRK3) gene and childhood-onset mood disorders. Am. J. Psychiatry 165(5), 610-616 (2008
122. Tadokoro K, Hashimoto R, Tatsumi M et al. Analysis of enhancer activity of a dinucleotide repeat polymorphism in the neurotrophin-3 gene and its association with bipolar disorder. Neuropsychobiology 50(3), 206-210 (2004
123. Otsuki K, Uchida S, Watanuki T et al. Altered expression of neurotrophic factors in patients with major depression. J. Psychiatr. Res. 42(14), 1145-1153 (2008
124. Walz JC, Andreazza AC, Frey BN et al. Serum neurotrophin-3 is increased during manic and depressive episodes in bipolar disorder. Neurosci. Lett. 415(1), 87-89 (2007
125. Fernandes BS, Gama CS, Walz JC et al. Increased neurotrophin-3 in drug-free subjects with bipolar disorder during manic and depressive episodes. J. Psychiatr. Res. 44(9), 561-565 (2010
126. Secolin R, Banzato CE, Mella LF et al. Refinement of chromosome 3p22.3 region and identification of a susceptibility gene for bipolar affective disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet. 162B(2), 163-168 (2013
127. Barbosa IG, Huguet RB, Neves FS et al. Impaired nerve growth factor homeostasis in patients with bipolar disorder. World J. Biol. Psychiatry 12(3), 228-232 (2011
128. Walz JC, Magalhaes PV, Giglio LM et al. Increased serum neurotrophin-4/5 levels in bipolar disorder. J. Psychiatr. Res. 43(7), 721-723 (2009
129. Petryshen TL, Sabeti PC, Aldinger KA et al. Population genetic study of the brain-derived neurotrophic factor (BDNF) gene. Mol. Psychiatry 15(8), 810-815 (2010
130. Nugent AC, Diazgranados N, Carlson PJ et al. Neural correlates of rapid antidepressant response to ketamine in bipolar disorder. Bipolar Disord. doi:10.1111/bdi.12118 (2013) (Epub ahead of print
131. Nugent AC, Carlson PJ, Bain EE, et al. Mood stabilizer treatment increases serotonin type 1A receptor binding in bipolar depression. J. Psychopharmacol. 27(10), 894-902 (2013